IN2012DN06616A - - Google Patents

Info

Publication number
IN2012DN06616A
IN2012DN06616A IN6616DEN2012A IN2012DN06616A IN 2012DN06616 A IN2012DN06616 A IN 2012DN06616A IN 6616DEN2012 A IN6616DEN2012 A IN 6616DEN2012A IN 2012DN06616 A IN2012DN06616 A IN 2012DN06616A
Authority
IN
India
Prior art keywords
osas
additional active
eszopiclone
zaleplon
zolpidem
Prior art date
Application number
Inventor
Leland Wilson
Peter Tam
Thomas Najarian
Charles H Bowden
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306177&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN06616(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vivus Inc filed Critical Vivus Inc
Publication of IN2012DN06616A publication Critical patent/IN2012DN06616A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil eszopiclone Zolpidem zaleplon and phentermine.
IN6616DEN2012 2010-01-07 2011-01-07 IN2012DN06616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29312910P 2010-01-07 2010-01-07
PCT/US2011/020588 WO2011085256A2 (en) 2010-01-07 2011-01-07 Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent

Publications (1)

Publication Number Publication Date
IN2012DN06616A true IN2012DN06616A (en) 2015-10-23

Family

ID=44306177

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6616DEN2012 IN2012DN06616A (en) 2010-01-07 2011-01-07

Country Status (13)

Country Link
US (3) US20110224196A1 (en)
EP (1) EP2521546A4 (en)
JP (1) JP2013516488A (en)
KR (1) KR20120101588A (en)
CN (1) CN102781446A (en)
AU (1) AU2011203970A1 (en)
BR (1) BR112012016799A2 (en)
CA (1) CA2786026A1 (en)
CL (1) CL2012001844A1 (en)
IL (1) IL220552A0 (en)
IN (1) IN2012DN06616A (en)
MX (1) MX2012007813A (en)
WO (1) WO2011085256A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20160045527A1 (en) * 2014-08-14 2016-02-18 Vivus, Inc. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
US20160367503A1 (en) * 2015-06-20 2016-12-22 Cary Erwin Fechter Combination Medication for Neuro-Degenerative Diseases
JP6930969B2 (en) 2015-07-08 2021-09-01 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー Treatment of prefrontal cortex processing disorders, gait and limb disorders
PL3423062T3 (en) * 2016-05-11 2020-12-28 Jan Hedner Sultiame for the treatment of sleep apnea
EP3846794A4 (en) * 2018-09-06 2022-06-22 Monash University Method of treating a sleep breathing disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021A (en) * 1847-03-20 Jambs haworth
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2706767B1 (en) * 1993-06-22 1995-09-08 Lafon Labor
ATE294577T1 (en) * 1999-02-24 2005-05-15 Univ Cincinnati USE OF SULFAMATE DERIVATIVES TO TREAT IMPULSIVE DISORDERS
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
SE0000601D0 (en) * 2000-02-24 2000-02-24 Jan Hedner Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure
FR2849029B1 (en) * 2002-12-20 2005-03-18 Lafon Labor PROCESS FOR THE PREPARATION AND CRYSTALLINE FORMS OF OPTICAL ENANTIOMERS OF MODAFINIL.
US20040229943A1 (en) * 2003-05-16 2004-11-18 Cephalon Inc Analeptic and drug combinations
EP1516869A1 (en) * 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
PT1691811E (en) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
SE0400378D0 (en) * 2004-02-17 2004-02-17 Jan Hedner Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US8512751B2 (en) * 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
KR20080059208A (en) * 2005-09-16 2008-06-26 세레우사이언스 아베 Method and means of preventing and treating sleep disordered breathing
EP2124909A4 (en) * 2006-12-19 2010-03-31 Univ Virginia Combined effects of topiramate and ondansetron on alcohol consumption
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
EP2142183A2 (en) * 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
CA2688430A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders

Also Published As

Publication number Publication date
US20140094511A1 (en) 2014-04-03
US20110224196A1 (en) 2011-09-15
US20150231110A1 (en) 2015-08-20
BR112012016799A2 (en) 2019-10-08
IL220552A0 (en) 2012-08-30
KR20120101588A (en) 2012-09-13
JP2013516488A (en) 2013-05-13
AU2011203970A1 (en) 2012-07-12
CA2786026A1 (en) 2011-07-14
EP2521546A4 (en) 2013-06-26
EP2521546A2 (en) 2012-11-14
WO2011085256A2 (en) 2011-07-14
MX2012007813A (en) 2012-08-01
WO2011085256A3 (en) 2011-11-03
CN102781446A (en) 2012-11-14
CL2012001844A1 (en) 2013-03-22

Similar Documents

Publication Publication Date Title
IN2012DN06616A (en)
EA201390827A1 (en) USE OF LAKININIMODE TO REDUCE FATIGUE, IMPROVE FUNCTIONAL CONDITION AND IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH MULTIPLE SCLEROSIS
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MY174080A (en) Use of dpp iv inhibitors
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
GEP20166455B (en) Methods of administering pirfenidone therapy
WO2011041632A3 (en) Combination therapies for the treatment of obesity
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
MX2014002171A (en) Combination treatments for hepatitis c.
MX337614B (en) Treatment of lupus nephritis using laquinimod.
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
MY173215A (en) Acetylcysteine compositions and methods of use thereof
EA201490378A1 (en) TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β
MX2010009623A (en) 1-benzyl-3-hydroxymethylindazoiî¹e derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1.
WO2010151565A3 (en) Combination therapies for the treatment of obesity
MX2010009625A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
MX2013004873A (en) Methods and compositions for treating hiv-associated diarrhea.
MX2013003060A (en) Combination therapy for treating hcv infection.
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
WO2010151503A3 (en) Combination therapies for the treatment of obesity
MX2008002456A (en) Use of ambroxol for the treatment of rhinovirus infections.